{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:14:23Z","timestamp":1791810863962,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T00:00:00Z","timestamp":1672012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To evaluate the effectiveness and safety of Selective Laser Trabeculoplasty (SLT) with the SLT mode of the VISULAS<jats:sup>\u00ae<\/jats:sup> green laser in patients with primary open-angle glaucoma (POAG).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This prospective, interventional multicenter clinical investigation included patients with POAG who either needed a treatment escalation because the individual intraocular pressure (IOP) target was not met or treatment initiation and had an IOP\u2009\u2265\u200917\u00a0mmHg at baseline in the study eye. The study was conducted in five research centers across Germany. Approximately 100 laser applications were delivered to 360\u00b0 of the trabecular meshwork. Glaucoma medications were not modified during the 3-month follow-up to allow evaluation of the sole effect of VISULAS<jats:sup>\u00ae<\/jats:sup> green with SLT. Efficacy outcomes were postoperatively absolute and relative IOP changes at 1 and 3\u00a0months. Safety outcomes analyzed the rate of intra- and postoperative adverse events.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-four eyes of 34 POAG patients were included. The overall mean number of preoperative glaucoma medications was 2.2\u2009\u00b1\u20091.4 in 29 treated eyes, 5 eyes were treatment na\u00efve. Mean baseline IOP (mmHg) was 21.0\u2009\u00b1\u20092.69 and was reduced by \u2212\u20093.53\u2009\u00b1\u20093.34 [95% CI \u2212\u20094.61; \u2212\u20092.45] and \u2212\u20093.59\u2009\u00b1\u20093.41 [95% CI \u2212\u20094.64; \u2212\u20092.53] at the 1- and 3-month follow-up, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), with 48.5% of cases achieving a\u2009\u2265\u200920% IOP reduction at 3\u00a0months [95% CI\u2009=\u200930.8%; 66.5%]. The mean relative IOP reduction was \u2212\u200916.4% and \u2212\u200916.3% at 1 and 3\u00a0months, respectively (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Potentially device- or procedure-related adverse events were mild to moderate and included 3 postoperative IOP-spikes and 6 reports regarding eye pain and discomfort. All were resolved without sequelae.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>SLT performed with the VISULAS<jats:sup>\u00ae<\/jats:sup> green laser achieved clinically significant additional IOP reductions in medically treated as well as in treatment na\u00efve eyes with POAG and there were no relevant safety issues. The results are comparable to other reported SLT studies.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10792-022-02617-7","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T18:02:31Z","timestamp":1672077751000},"page":"2215-2224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effectiveness and safety of VISULAS\u00ae green selective laser trabeculoplasty: a prospective, interventional multicenter clinical investigation"],"prefix":"10.1007","volume":"43","author":[{"given":"Karin R.","family":"Pillunat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian T. A.","family":"Kretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Koinzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ehlken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz E.","family":"Pillunat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Klabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,26]]},"reference":[{"key":"2617_CR1","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/s0002-9394(98)00223-2","volume":"126","author":"Collaborative Normal-Tension Glaucoma Study Group","year":"1998","unstructured":"Collaborative Normal-Tension Glaucoma Study Group (1998) Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 126:487\u2013497. https:\/\/doi.org\/10.1016\/s0002-9394(98)00223-2","journal-title":"Am J Ophthalmol"},{"key":"2617_CR2","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/archopht.120.10.1268","volume":"120","author":"A Heijl","year":"2002","unstructured":"Early Manifest Glaucoma Trial G, Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M (2002) Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol 120:1268\u20131279. https:\/\/doi.org\/10.1001\/archopht.120.10.1268","journal-title":"Arch Ophthalmol"},{"key":"2617_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK II, Wilson MR, Gordon MO (2002) The Ocular hypertension treatment study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 120:701\u2013713. https:\/\/doi.org\/10.1001\/archopht.120.6.701(Discussion 829-730).","journal-title":"Arch Ophthalmol"},{"key":"2617_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/ICU.0000000000000732","volume":"32","author":"M Toteberg-Harms","year":"2021","unstructured":"Toteberg-Harms M, Meier-Gibbons F (2021) Is laser trabeculoplasty the new star in glaucoma treatment? Curr Opin Ophthalmol 32:141\u2013147. https:\/\/doi.org\/10.1097\/ICU.0000000000000732","journal-title":"Curr Opin Ophthalmol"},{"key":"2617_CR5","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/IJG.0b013e31817d2386","volume":"17","author":"T Realini","year":"2008","unstructured":"Realini T (2008) Selective laser trabeculoplasty: a review. J Glaucoma 17:497\u2013502. https:\/\/doi.org\/10.1097\/IJG.0b013e31817d2386","journal-title":"J Glaucoma"},{"key":"2617_CR6","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/IJG.0b013e318218287f","volume":"21","author":"LJ Katz","year":"2012","unstructured":"Group SLMS, Katz LJ, Steinmann WC, Kabir A, Molineaux J, Wizov SS, Marcellino G (2012) Selective laser trabeculoplasty versus medical therapy as initial treatment of glaucoma: a prospective, randomized trial. J Glaucoma 21:460\u2013468. https:\/\/doi.org\/10.1097\/IJG.0b013e318218287f","journal-title":"J Glaucoma"},{"key":"2617_CR7","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","volume":"393","author":"G Gazzard","year":"2019","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, Ambler G, Bunce C, Wormald R, Nathwani N, Barton K, Rubin G, Buszewicz M, Li GHTTSG (2019) Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet 393:1505\u20131516. https:\/\/doi.org\/10.1016\/S0140-6736(18)32213-X","journal-title":"Lancet"},{"key":"2617_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.09.009","author":"G Gazzard","year":"2022","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, Adeleke M, Vickerstaff V, Ambler G, Hunter R, Bunce C, Nathwani N, Barton K, Li GHTTSG (2022) LiGHT trial: 6-year results of primary selective laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension. Ophthalmology. https:\/\/doi.org\/10.1016\/j.ophtha.2022.09.009","journal-title":"Ophthalmology"},{"key":"2617_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/IJG.0b013e3181e3d2c1","volume":"20","author":"E Martow","year":"2011","unstructured":"Martow E, Hutnik CM, Mao A (2011) SLT and adjunctive medical therapy: a prediction rule analysis. J Glaucoma 20:266\u2013270. https:\/\/doi.org\/10.1097\/IJG.0b013e3181e3d2c1","journal-title":"J Glaucoma"},{"key":"2617_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/aos.13094","volume":"94","author":"KR Pillunat","year":"2016","unstructured":"Pillunat KR, Spoerl E, Elfes G, Pillunat LE (2016) Preoperative intraocular pressure as a predictor of selective laser trabeculoplasty efficacy. Acta Ophthalmol 94:692\u2013696. https:\/\/doi.org\/10.1111\/aos.13094","journal-title":"Acta Ophthalmol"},{"key":"2617_CR11","volume-title":"Terminology and guidelines for Glaucoma The","author":"Society EG","year":"2021","unstructured":"Society EG (2021) Terminology and guidelines for Glaucoma The, 5th edn. PubliComm, Savona, Italy","edition":"5"},{"key":"2617_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/9783527648962","volume-title":"Optical devices in ophthalmology and optometry: technology, design principles, and clinical applications","author":"M Kaschke","year":"2014","unstructured":"Kaschke M (2014) Optical devices in ophthalmology and optometry: technology, design principles, and clinical applications. Wiley-VCH Verlag, Weinheim"},{"key":"2617_CR13","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1093\/biomet\/26.4.404","volume":"26","author":"CP Clopper","year":"1934","unstructured":"Clopper CP, Pearson ES (1934) The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404\u2013413","journal-title":"Biometrika"},{"key":"2617_CR14","unstructured":"Team RC (2017) R: a language and environment for statistical computing"},{"key":"2617_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.survophthal.2014.06.006","volume":"60","author":"MO Wong","year":"2015","unstructured":"Wong MO, Lee JW, Choy BN, Chan JC, Lai JS (2015) Systematic review and meta-analysis on the efficacy of selective laser trabeculoplasty in open-angle glaucoma. Surv Ophthalmol 60:36\u201350. https:\/\/doi.org\/10.1016\/j.survophthal.2014.06.006","journal-title":"Surv Ophthalmol"},{"key":"2617_CR16","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/eye.2017.273","volume":"32","author":"A Garg","year":"2018","unstructured":"Garg A, Gazzard G (2018) Selective laser trabeculoplasty: past, present, and future. Eye (Lond) 32:863\u2013876. https:\/\/doi.org\/10.1038\/eye.2017.273","journal-title":"Eye (Lond)"},{"key":"2617_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1136\/bjophthalmol-2020-316178","volume":"105","author":"MOM Wong","year":"2021","unstructured":"Wong MOM, Lai IS, Chan PP, Chan NC, Chan AY, Lai GW, Chiu VS, Leung CK (2021) Efficacy and safety of selective laser trabeculoplasty and pattern scanning laser trabeculoplasty: a randomised clinical trial. Br J Ophthalmol 105:514\u2013520. https:\/\/doi.org\/10.1136\/bjophthalmol-2020-316178","journal-title":"Br J Ophthalmol"},{"key":"2617_CR18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/opo.12611","volume":"39","author":"O Chadwick","year":"2019","unstructured":"Chadwick O, Chia SN, Rotchford A (2019) Establishing an allied health professional delivered selective laser trabeculoplasty service in Scotland. Ophthalmic Physiol Opt 39:216\u2013223. https:\/\/doi.org\/10.1111\/opo.12611","journal-title":"Ophthalmic Physiol Opt"},{"key":"2617_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ogla.2019.11.010","volume":"3","author":"B Kuley","year":"2020","unstructured":"Kuley B, Zheng CX, Zhang QE, Hamershock RA, Lin MM, Moster SJ, Murphy J, Moster MR, Schmidt C, Lee D, Pro MJ (2020) Predictors of success in selective laser trabeculoplasty. Ophthalmol Glaucoma 3:97\u2013102. https:\/\/doi.org\/10.1016\/j.ogla.2019.11.010","journal-title":"Ophthalmol Glaucoma"},{"key":"2617_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40662-016-0041-y","volume":"3","author":"M De Keyser","year":"2016","unstructured":"De Keyser M, De Belder M, De Belder S, De Groot V (2016) Where does selective laser trabeculoplasty stand now? A review Eye Vis (Lond) 3:10. https:\/\/doi.org\/10.1186\/s40662-016-0041-y","journal-title":"A review Eye Vis (Lond)"},{"key":"2617_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.preteyeres.2016.12.004","volume":"57","author":"T Carreon","year":"2017","unstructured":"Carreon T, van der Merwe E, Fellman RL, Johnstone M, Bhattacharya SK (2017) Aqueous outflow - A continuum from trabecular meshwork to episcleral veins. Prog Retin Eye Res 57:108\u2013133. https:\/\/doi.org\/10.1016\/j.preteyeres.2016.12.004","journal-title":"Prog Retin Eye Res"},{"key":"2617_CR22","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1136\/bjophthalmol-2019-315489","volume":"104","author":"P Alaghband","year":"2020","unstructured":"Alaghband P, Galvis EA, Daas A, Nagar A, Beltran-Agullo L, Khawaja AP, Goyal S, Lim KS (2020) Predictors of selective laser trabeculoplasty success in open angle glaucoma or ocular hypertension: does baseline tonography have a predictive role? Br J Ophthalmol 104:1390\u20131393. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315489","journal-title":"Br J Ophthalmol"},{"key":"2617_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2147\/OPTH.S84996","volume":"10","author":"J Song","year":"2016","unstructured":"Song J (2016) Complications of selective laser trabeculoplasty: a review. Clin Ophthalmol 10:137\u2013143. https:\/\/doi.org\/10.2147\/OPTH.S84996","journal-title":"Clin Ophthalmol"},{"key":"2617_CR24","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1080\/17512433.2021.1981860","volume":"14","author":"YS Chen","year":"2021","unstructured":"Chen YS, Hung HT, Guo SP, Chang HC (2021) Effects of anti-inflammatory treatment on efficacy of selective laser trabeculoplasty: a systematic review and meta-analysis. Expert Rev Clin Pharmacol 14:1527\u20131534. https:\/\/doi.org\/10.1080\/17512433.2021.1981860","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2617_CR25","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1016\/S0161-6420(98)91129-0","volume":"105","author":"MA Latina","year":"1998","unstructured":"Latina MA, Sibayan SA, Shin DH, Noecker RJ, Marcellino G (1998) Q-switched 532-nm Nd:YAG laser trabeculoplasty (selective laser trabeculoplasty): a multicenter, pilot, clinical study. Ophthalmology 105:2082\u20132088. https:\/\/doi.org\/10.1016\/S0161-6420(98)91129-0. (Discussion 2089\u20132090)","journal-title":"Ophthalmology"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02617-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-022-02617-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-022-02617-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T15:05:48Z","timestamp":1688137548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-022-02617-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["2617"],"URL":"https:\/\/doi.org\/10.1007\/s10792-022-02617-7","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,26]]},"assertion":[{"value":"12 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K. R. P. has received lecture fees from Allergan, Santen and Novartis.\nF.T.A.K. has received compensation for consulting, lectures, travel costs and grants from BVI, Carl Zeiss Meditec, Teleon, Hoya, VSY, Bausch & Lomb.\nS.K. has received compensation for consulting from Carl Zeiss Meditec AG.\nC.E. has received lecture fees from Bayer and Allergan.\nL. E. P. has received lecture fees from Allergan and Santen and is on the Advisory \nBoard for Allergan, Santen and Aerie, and received grant support from Novartis.\nK.K. has received lecture fees from Abbvie, Glaukos, iStar medical, Oertli and Carl Zeiss Meditec, has received compensation for consulting from Carl Zeiss Meditec and is on the Advisory Board for Abbvie, iStar Medical, Oertli and Santen.\nNone of the authors has any financial interest or any conflict of interest related to the \nsubject matter.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"K. R. P. has received lecture fees from Allergan, Santen and Novartis. F.T.A.K. has received compensation for consulting, lectures, travel costs and grants from BVI, Carl Zeiss Meditec, Teleon, Hoya, VSY, Bausch & Lomb. S.K. has received compensation for consulting from Carl Zeiss Meditec AG. C.E. has received lecture fees from Bayer and Allergan. L. E. P. has received lecture fees from Allergan and Santen and is on the Advisory. Board for Allergan, Santen and Aerie, and received grant support from Novartis.K.K. has received lecture fees from Abbvie, Glaukos, iStar medical, Oertli and Carl Zeiss Meditec, has received compensation for consulting from Carl Zeiss Meditec and is on the Advisory Board for Abbvie, iStar Medical, Oertli and Santen. None of the authors has any financial interest or any conflict of interest related to the subject matter.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and was approved by the responsible Ethic Commission at the TU Dresden (MPG ff-EK-24012020) and the involved local Ethic Commissions at the participating study sites as well as by the German Competent Authority BfArM (EUDAMED: CIV-19\u201312-031046). The study is registered at clinicaltrials.gov under NCT04519814.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all study participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}